Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).
Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaStereotactic body radiation therapySystemic treatmentSystemic therapyLess benefitCompletion of SBRTRole of SBRTHigh expressionBody radiation therapyRenal cell carcinomaT-testStudent's t-testHypoxia-related genesCommon histologyOligoprogressive diseaseClinicopathologic characteristicsMedian ageFischer's exactClinical benefitCell carcinomaClear cellsRadiation therapyTreatment durationTreatment changesIncreased expression